Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
Recruiting
Observational Study
Atopic Dermatitis (AD)
Atopic Dermatitis (Eczema)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 15 (estimated)
- Sponsor
- Hôpitaux Drôme Nord · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Nemolizumab is a a humanised anti-IL-31 monoclonal antibody that has proven to be effective and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 18 years and older.
* Patients with moderate-to-severe Atopic Dermatitis who require systemic treatment with nemolizumab
* Patients affiliated with or entitled to a social security scheme.
* Patients capable of giving informed consent.
* Patients who have receive…
Contacts
No contact information available.